<DOC>
	<DOCNO>NCT02959853</DOCNO>
	<brief_summary>After age 40 , gradual decline production testosterone . Among obese men , decline testosterone level exacerbate suppression hypothalamic-pituitary-gonadal axis hyperestrogenemia . The high expression aromatase enzyme adipose tissue enhances conversion androgens estrogens turn exert negative feedback hypothalamus pituitary , lead inhibition production gonadotropin-releasing hormone ( GnRH ) , luteinizing hormone ( LH ) follicle stimulate hormone ( FSH ) , consequence , testosterone testis result hypogonadotropic hypogonadism ( HH ) . Though bone loss well recognize side effect AI certain population , woman breast cancer , HH obese men present high level circulate estrogen could potentially prevent bone loss , estradiol main regulator male skeleton . This study design determine aromatase inhibitor combination weight loss , compare weight loss alone , positive effect muscle strength , symptom hypogonadism , body composition without negatively impact bone mineral density bone quality . Results study help determine certain group obese patient would benefit therapy aromatase inhibitor .</brief_summary>
	<brief_title>Aromatase Inhibitors Weight Loss Severely Obese Hypogonadal Male Veterans ( Pilot )</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>severely obese ( BMI &gt; = 35 ) male veteran hypogonadotropic hypogonadism define low total testosterone ( low 300 ng/dl ) 3565 year age Luteinizing hormone ( LH ) low 9 U/L estradiol 40 pmol/l normal Free T4 ( FT4 ) , Thyroid Stimulating Hormone ( TSH ) , prolactin , cortisol , Adrenocorticotropic hormone ( ACTH ) , Insulinlike growth factor1 ( IGF1 ) level . Subjects must ambulatory , willing able provide write informed consent clinical biochemical evidence pituitary hypothalamic disease ongoing illness , opinion investigator , could prevent subject complete study med know affect gonadal hormone , steroid hormonebinding globulin bone metabolism , e.g. , androgens estrogen glucocorticoid phenytoin bisphosphonates medication know interfere anastrozole metabolism , e.g . tamoxifen estrogens disease know interfere bone metabolism osteoporosis hyperparathyroidism untreated hyperthyroidism osteomalacia chronic liver disease renal failure hypercortisolism malabsorption immobilization patient Total T score lower 2.0 Lumbar Spine Left Femur . patient symptomatic prostate disease , prostate carcinoma , elevate serum Prostatespecific antigen ( PSA ) &gt; 4 ng/ml &gt; 3 subject family history prostate cancer among 1st degree relative need urologic evaluation admission study hematocrit great 50 % untreated severe obstructive sleep apnea severe low urinary tract symptom International Prostate Symptom Score ( IPSS ) 19 documented heart failure cardiovascular disease liver disease excessive alcohol substance abuse unstable weight ( change weight Â± 2 kg ) last 3 month history bariatric surgery subject elevate liver enzymes alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) , Alkaline phosphatase ( ALP ) , bilirubin great twice upper limit normal .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Severe obesity</keyword>
</DOC>